At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MNMD Mind Medicine (MindMed) Inc.
Market Closed 05-17 16:00:00 EDT
8.22
-0.43
-4.97%
盘后8.42
+0.20+2.43%
19:46 EDT
High8.78
Low8.22
Vol1.01M
Open8.67
D1 Closing8.65
Amplitude6.47%
Mkt Cap590.79M
Tradable Cap474.98M
Total Shares71.87M
T/O8.43M
T/O Rate1.74%
Tradable Shares57.78M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.